T 1651/11 (Apremilast against psoriasis/CELGENE) of 17.03.2015

European Case Law Identifier: ECLI:EP:BA:2015:T165111.20150317
Date of decision: 17 March 2015
Case number: T 1651/11
Petition for review of: -
Application number: 03721414.5
IPC class: A61P 35/00 C07C 317/28 C07D 209/48 A61K 31/4035
Language of proceedings: English
Distribution: No distribution (D)
Download: Decision in English
OJ versions: No OJ links found
Other decisions for this case: -
Abstracts for this decision: -
Application title: (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE FOR USE IN TREATING PSORIASIS BY ORAL ADMINISTRATION
Applicant name: CELGENE CORPORATION
Opponent name: Ratiopharm GmbH
Board: 3.3.01
Headnote: -
Relevant legal provisions: European Patent Convention Art 100(c) 1973 European Patent Convention Art 123(2)
Keywords: Amendments - added subject-matter (yes)
Catchword: -
Cited cases: G 0003/89 G 0002/10
Citing cases: -

Order

For these reasons it is decided that:

The appeal is dismissed.